Title:
【発明の名称】医 薬
Document Type and Number:
Japanese Patent JP3026840
Kind Code:
B2
Abstract:
Formulation comprises a particulate medicament (I) e.g. salmeterol, salbutamol, fluticasone propionate, becolomethasone dipropionate and a fluorocarbon or hydrogen-contg chlorofluorocarbon propellant. Also claimed are the prepn of the surface-modified medicament and a canister for delivering metered doses of the aerosol formulation. Pref., (I) is salmeterol xinafoate (Ia); salbutamol sulphate; fluticascone propionate; beclomethasone dipropionate; or a combination of salmeterol xinafoate and fluticasone propionate; or salbutamol and beclomethasone dipropionate. The propellant is pref. 1,1,1,2-tetrafluoroethane (II). (I) is present in an amt. of 0.005-10% wt. based on the total wt. of the formulation e.g. a salbutamol salt and 1,1,1,2-tetrafluoroethane in a ratio of 0.05:18 by wt. Surface-modified (I) are prepd. by admixture of particulate (I) with a non-polar, non-solvent liq. followed by removal of the lid.
More Like This:
| JP2005512740 | Weighing inhaler |
| JPWO2006118246 | Transdermal absorption promoter |
| JP2022538911 | Sustained-release composition of endoxifen |
Inventors:
Akehurst, Racial Anne
Taylor, Anthony James
Wyatt, David Andrew
Taylor, Anthony James
Wyatt, David Andrew
Application Number:
JP51057392A
Publication Date:
March 27, 2000
Filing Date:
December 04, 1992
Export Citation:
Assignee:
GLAXO GROUP LTD.
International Classes:
A61K47/06; A61K9/00; A61K9/12; A61K9/72; A61K31/00; A61K31/02; A61K31/135; A61K31/137; A61K31/138; A61K31/167; A61K31/352; A61K31/44; A61K31/4402; A61K31/4458; A61K31/4535; A61K31/4741; A61K31/48; A61K31/522; A61K31/56; A61K31/57; A61K31/573; A61K45/06; A61M11/04; A61M15/00; A61P11/00; A61P11/02; A61P11/06; A61P11/08; B65D83/14; B65D83/52; A61K; (IPC1-7): A61K31/137; A61K9/12; A61K9/72; A61K31/56; A61K47/06
Attorney, Agent or Firm:
Kazuo Shamoto (4 outside)